Handelsbanken Fonder AB Has $152.88 Million Holdings in Abbott Laboratories $ABT

Handelsbanken Fonder AB raised its position in Abbott Laboratories (NYSE:ABT) by 11.4% during the fourth quarter, Holdings Channel.com reports. The institutional investor owned 1,220,202 shares of the healthcare product maker’s stock after purchasing an additional 124,733 shares during the quarter. Handelsbanken Fonder AB’s holdings in Abbott Laboratories were worth $152,879,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in ABT. Harbor Capital Advisors Inc. acquired a new stake in Abbott Laboratories in the 4th quarter valued at about $27,000. Cloud Capital Management LLC acquired a new stake in Abbott Laboratories in the 3rd quarter valued at about $29,000. Guerra Advisors Inc acquired a new stake in Abbott Laboratories in the 3rd quarter valued at about $31,000. Bridge Generations Wealth Management LLC acquired a new stake in Abbott Laboratories in the 3rd quarter valued at about $33,000. Finally, Copia Wealth Management acquired a new stake in Abbott Laboratories in the 3rd quarter valued at about $38,000. Institutional investors and hedge funds own 75.18% of the company’s stock.

Insider Buying and Selling at Abbott Laboratories

In related news, SVP Eric Shroff sold 709 shares of Abbott Laboratories stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $115.58, for a total transaction of $81,946.22. Following the transaction, the senior vice president owned 39,164 shares of the company’s stock, valued at $4,526,575.12. This trade represents a 1.78% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Daniel Gesua Sive Salvadori sold 885 shares of Abbott Laboratories stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $115.58, for a total transaction of $102,288.30. Following the transaction, the executive vice president directly owned 146,377 shares in the company, valued at $16,918,253.66. The trade was a 0.60% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 3,055 shares of company stock worth $353,097 over the last ninety days. 0.46% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several research firms have weighed in on ABT. Leerink Partners lowered their price objective on shares of Abbott Laboratories from $119.00 to $106.00 and set a “market perform” rating for the company in a research report on Tuesday, April 21st. TD Cowen lowered their price objective on shares of Abbott Laboratories from $137.00 to $115.00 and set a “buy” rating for the company in a research report on Friday, April 17th. Daiwa Securities Group cut shares of Abbott Laboratories from an “outperform” rating to a “neutral” rating and set a $92.00 price objective for the company. in a research report on Wednesday, April 22nd. Jefferies Financial Group lowered their price objective on shares of Abbott Laboratories from $145.00 to $135.00 and set a “buy” rating for the company in a research report on Friday, April 17th. Finally, JPMorgan Chase & Co. lowered their price target on shares of Abbott Laboratories from $123.00 to $110.00 and set an “overweight” rating for the company in a research report on Friday, April 17th. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have assigned a Hold rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $119.43.

Abbott Laboratories Stock Up 4.0%

Shares of NYSE:ABT opened at $87.82 on Tuesday. Abbott Laboratories has a one year low of $81.97 and a one year high of $139.06. The company has a 50 day moving average of $98.56 and a 200-day moving average of $112.98. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.39 and a quick ratio of 1.01. The stock has a market cap of $152.96 billion, a price-to-earnings ratio of 24.60, a P/E/G ratio of 1.41 and a beta of 0.65.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 EPS for the quarter, topping the consensus estimate of $1.14 by $0.01. Abbott Laboratories had a net margin of 13.90% and a return on equity of 17.62%. The company had revenue of $11.16 billion during the quarter, compared to analysts’ expectations of $10.99 billion. During the same quarter in the previous year, the company earned $1.09 EPS. Abbott Laboratories’s revenue was up 7.8% on a year-over-year basis. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. On average, sell-side analysts forecast that Abbott Laboratories will post 5.48 earnings per share for the current year.

Abbott Laboratories Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, May 15th. Investors of record on Wednesday, April 15th were paid a dividend of $0.63 per share. The ex-dividend date of this dividend was Wednesday, April 15th. This represents a $2.52 annualized dividend and a yield of 2.9%. Abbott Laboratories’s dividend payout ratio (DPR) is presently 70.59%.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.